Variable . | n (%) . | Mean (SD) . |
---|---|---|
Total population | 669 | — |
Male | 346 (51.7) | — |
Age (years) | — | 58.8 (8.2) |
White | 666 (99.6) | — |
Duration of diabetes (years) | — | 7.2 (5.2) |
Physiologic measurements | — | — |
BMI (kg/m2) | — | 31.2 (4.6) |
Systolic blood pressure (mmHg) | — | 139.7 (15.4) |
Diastolic blood pressure (mmHg) | — | 83.1 (8.9) |
Heart rate (bpm) | — | 73.8 (8.4) |
Medical history | — | — |
Angina-stable | 66 (9.9) | — |
Clinical history of MI | 26 (3.9) | — |
Hypertension | 541 (80.9) | — |
Hyperlipidemia | 106 (15.8) | — |
Percutaneous coronary intervention | 11 (1.6) | — |
Coronary artery bypass grafting | 13 (1.9) | — |
Transient ischemic attack | 13 (1.9) | — |
Stroke | 13 (1.9) | — |
Peripheral arterial disease | 21 (3.1) | — |
Diabetic retinopathy | 80 (12) | — |
Heart failure | 5 (0.7) | — |
Current smoker | 103 (15.4) | — |
Previous smoker | 146 (21.8) | — |
Neuropathy | 38 (5.7) | — |
Laboratory measurements | — | — |
HbA1c (%) | — | 7.9 (0.7) |
Fasting plasma glucose (mmol/L) | — | 9.8 (2.2) |
Total cholesterol (mmol/L) | — | 5.4 (1.0) |
Microalbuminuria | 96 (14.3) | — |
Macroalbuminuria | 8 (1.2) | — |
Drug therapy | — | |
Metformin monotherapy | 344 (51.4) | — |
Sulfonylurea monotherapy | 325 (48.6) | — |
Statin | 110 (16.4) | — |
β-Blocker | 161 (24.2) | — |
Angiotensin-converting enzyme inhibitor | 257 (38.4) | — |
Antiplatelet | 144 (21.5) | — |
Variable . | n (%) . | Mean (SD) . |
---|---|---|
Total population | 669 | — |
Male | 346 (51.7) | — |
Age (years) | — | 58.8 (8.2) |
White | 666 (99.6) | — |
Duration of diabetes (years) | — | 7.2 (5.2) |
Physiologic measurements | — | — |
BMI (kg/m2) | — | 31.2 (4.6) |
Systolic blood pressure (mmHg) | — | 139.7 (15.4) |
Diastolic blood pressure (mmHg) | — | 83.1 (8.9) |
Heart rate (bpm) | — | 73.8 (8.4) |
Medical history | — | — |
Angina-stable | 66 (9.9) | — |
Clinical history of MI | 26 (3.9) | — |
Hypertension | 541 (80.9) | — |
Hyperlipidemia | 106 (15.8) | — |
Percutaneous coronary intervention | 11 (1.6) | — |
Coronary artery bypass grafting | 13 (1.9) | — |
Transient ischemic attack | 13 (1.9) | — |
Stroke | 13 (1.9) | — |
Peripheral arterial disease | 21 (3.1) | — |
Diabetic retinopathy | 80 (12) | — |
Heart failure | 5 (0.7) | — |
Current smoker | 103 (15.4) | — |
Previous smoker | 146 (21.8) | — |
Neuropathy | 38 (5.7) | — |
Laboratory measurements | — | — |
HbA1c (%) | — | 7.9 (0.7) |
Fasting plasma glucose (mmol/L) | — | 9.8 (2.2) |
Total cholesterol (mmol/L) | — | 5.4 (1.0) |
Microalbuminuria | 96 (14.3) | — |
Macroalbuminuria | 8 (1.2) | — |
Drug therapy | — | |
Metformin monotherapy | 344 (51.4) | — |
Sulfonylurea monotherapy | 325 (48.6) | — |
Statin | 110 (16.4) | — |
β-Blocker | 161 (24.2) | — |
Angiotensin-converting enzyme inhibitor | 257 (38.4) | — |
Antiplatelet | 144 (21.5) | — |